Farnesoid X receptor activation induces the degradation of hepatotoxic 1‐deoxysphingolipids in non‐alcoholic fatty liver disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Farnesoid X receptor activation induces the degradation of hepatotoxic 1‐deoxysphingolipids in non‐alcoholic fatty liver disease
Authors
Keywords
-
Journal
LIVER INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-12-29
DOI
10.1111/liv.14340
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism
- (2018) Preeti Pathak et al. HEPATOLOGY
- FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
- (2018) Romeo Papazyan et al. JOURNAL OF LIPID RESEARCH
- Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation
- (2018) Zhibo Gai et al. MOLECULAR PHARMACOLOGY
- Ligand binding and heterodimerization with retinoid X receptor α (RXRα) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding
- (2018) Na Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
- (2018) Lulu Sun et al. NATURE MEDICINE
- Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
- (2017) Na Jiao et al. GUT
- Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance
- (2017) Geoffrey A. Preidis et al. JOURNAL OF CLINICAL INVESTIGATION
- Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
- (2017) Valerio Nobili et al. LIVER INTERNATIONAL
- Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus
- (2017) J. Mwinyi et al. PLoS One
- Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity
- (2016) Rainey E. Patterson et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
- (2016) R. Pencek et al. DIABETES OBESITY & METABOLISM
- Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters
- (2016) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction
- (2016) Irina Alecu et al. JOURNAL OF LIPID RESEARCH
- Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway
- (2016) Irina Alecu et al. JOURNAL OF LIPID RESEARCH
- Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes
- (2016) Regina Krattinger et al. LIFE SCIENCES
- Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis
- (2015) Jonathan Y. Xia et al. Cell Metabolism
- Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis
- (2015) Chrysi Koliaki et al. Cell Metabolism
- Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice
- (2015) Zhibo Gai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?
- (2015) Alaa Othman et al. Journal of Clinical Lipidology
- Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
- (2015) D. Lee Gorden et al. JOURNAL OF LIPID RESEARCH
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
- (2015) Sungsoon Fang et al. NATURE MEDICINE
- Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
- (2015) Changtao Jiang et al. Nature Communications
- All-trans retinoic acid regulates hepatic bile acid homeostasis
- (2014) Fan Yang et al. BIOCHEMICAL PHARMACOLOGY
- CerS2 Haploinsufficiency Inhibits β-Oxidation and Confers Susceptibility to Diet-Induced Steatohepatitis and Insulin Resistance
- (2014) Suryaprakash Raichur et al. Cell Metabolism
- Lowering Plasma 1-Deoxysphingolipids Improves Neuropathy in Diabetic Rats
- (2014) Alaa Othman et al. DIABETES
- Altered sphingoid base profiles in type 1 compared to type 2 diabetes
- (2014) Nancy Wei et al. Lipids in Health and Disease
- Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal
- (2014) Johannes Schmitt et al. LIVER INTERNATIONAL
- The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes
- (2014) Carlos A. Schaffner et al. LIVER INTERNATIONAL
- Genome-Wide Binding and Transcriptome Analysis of Human Farnesoid X Receptor in Primary Human Hepatocytes
- (2014) Le Zhan et al. PLoS One
- Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease
- (2014) Adil Mardinoglu et al. Nature Communications
- The adipokine/ceramide axis: Key aspects of insulin sensitization
- (2013) Jonathan Y. Xia et al. BIOCHIMIE
- Deoxysphingolipids, Novel Biomarkers for Type 2 Diabetes, Are Cytotoxic for Insulin-Producing Cells
- (2013) R. A. Zuellig et al. DIABETES
- Dissociation of Intestinal and Hepatic Activities of FXR and LXR Supports Metabolic Effects of Terminal Ileum Interposition in Rodents
- (2013) A. Mencarelli et al. DIABETES
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
- (2013) Jennifer E. Lambert et al. GASTROENTEROLOGY
- Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor inLdlr−/−mice versus hamsters
- (2013) Christophe Gardès et al. JOURNAL OF LIPID RESEARCH
- The Problem of Establishing Relationships between Hepatic Steatosis and Hepatic Insulin Resistance
- (2012) Robert V. Farese et al. Cell Metabolism
- Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
- (2012) Luciano Adorini et al. DRUG DISCOVERY TODAY
- Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver
- (2012) Santhosh Satapati et al. JOURNAL OF LIPID RESEARCH
- Cytochrome P4504f, a potential therapeutic target limiting neuroinflammation
- (2011) Neha Sehgal et al. BIOCHEMICAL PHARMACOLOGY
- Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?
- (2011) A. Othman et al. DIABETOLOGIA
- Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice
- (2011) Tsutomu Matsubara et al. HEPATOLOGY
- Ceramides as modulators of cellular and whole-body metabolism
- (2011) Benjamin T. Bikman et al. JOURNAL OF CLINICAL INVESTIGATION
- Tissue-specific function of farnesoid X receptor in liver and intestine
- (2011) Yan Zhu et al. PHARMACOLOGICAL RESEARCH
- Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
- (2010) X. X. Wang et al. DIABETES
- Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis
- (2010) Sayeepriyadarshini Anakk et al. JOURNAL OF CLINICAL INVESTIGATION
- PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid -Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease
- (2010) James P. Hardwick et al. PPAR Research
- FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
- (2009) Sabrina Cipriani et al. JOURNAL OF LIPID RESEARCH
- Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases
- (2008) James P. Hardwick BIOCHEMICAL PHARMACOLOGY
- Ceramide Synthase Inhibition by Fumonisin B1Causes Accumulation of 1-Deoxysphinganine
- (2008) Nicholas C. Zitomer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started